RankingsPricing
  1. US-listed companies
  2. NeuBase Therapeutics, Inc.
  3. Financials
  4. Return on equity (%)

NeuBase Therapeutics, Inc.NBSE

Market cap
$1.41M
P/E ratio
SummaryFinancials
Period EndReturn on equity (%) (Million USD)YoY (%)
Sep 30, 2022-87.4+46.87%
Sep 30, 2021-59.5-29.25%
Sep 30, 2020-84.1-67.34%
Sep 30, 2019-257.6+228.36%
Sep 30, 2018-78.4-21.24%
Sep 30, 2017-99.6+30.38%
Sep 30, 2016-76.4+74.03%
Sep 30, 2015-43.9-23.04%
Sep 30, 2014-57-61.20%
Sep 30, 2013-147

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)